CA2118012A1 - Variantes du facteur de croissance des hepatocytes - Google Patents

Variantes du facteur de croissance des hepatocytes

Info

Publication number
CA2118012A1
CA2118012A1 CA002118012A CA2118012A CA2118012A1 CA 2118012 A1 CA2118012 A1 CA 2118012A1 CA 002118012 A CA002118012 A CA 002118012A CA 2118012 A CA2118012 A CA 2118012A CA 2118012 A1 CA2118012 A1 CA 2118012A1
Authority
CA
Canada
Prior art keywords
variant
amino acid
hgf
huhgf
wild
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002118012A
Other languages
English (en)
Inventor
Paul J. Godowski
Nathalie A. Lokker
Melanie R. Mark
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/885,971 external-priority patent/US5328837A/en
Priority claimed from US07/884,811 external-priority patent/US5316921A/en
Application filed by Individual filed Critical Individual
Publication of CA2118012A1 publication Critical patent/CA2118012A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002118012A 1992-05-18 1993-05-17 Variantes du facteur de croissance des hepatocytes Abandoned CA2118012A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US07/884,811 1992-05-18
US07/885,971 US5328837A (en) 1992-05-18 1992-05-18 Hepatocyte growth factor protease domain variants
US07/884,811 US5316921A (en) 1992-05-18 1992-05-18 Single-chain hepatocyte growth factor variants
US07/885,971 1992-05-18
PCT/US1993/004648 WO1993023541A1 (fr) 1992-05-18 1993-05-17 Variantes du facteur de croissance des hepatocytes

Publications (1)

Publication Number Publication Date
CA2118012A1 true CA2118012A1 (fr) 1993-11-25

Family

ID=27128741

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002118012A Abandoned CA2118012A1 (fr) 1992-05-18 1993-05-17 Variantes du facteur de croissance des hepatocytes

Country Status (10)

Country Link
US (1) US5547856A (fr)
EP (1) EP0642580B1 (fr)
JP (2) JPH07508420A (fr)
AT (1) ATE222603T1 (fr)
CA (1) CA2118012A1 (fr)
DE (1) DE69332221T2 (fr)
DK (1) DK0642580T3 (fr)
ES (1) ES2181689T3 (fr)
PT (1) PT642580E (fr)
WO (1) WO1993023541A1 (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566098B1 (en) 1990-09-14 2003-05-20 The United States Of America As Represented By The Department Of Health And Human Services DNA encoding truncated hepatocyte growth factor variants
EP0805203B1 (fr) * 1992-09-18 2007-08-01 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Utilisation medicale d'un anticorps or d'un fragment d'un anticorps dirigé contre le domaine extracellulaire de Met pour la prévention de métastases.
ZA9510982B (en) * 1994-12-27 1996-08-22 Snow Brand Milk Products Co Ltd TCF mutant
US5646036A (en) * 1995-06-02 1997-07-08 Genentech, Inc. Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies
US6214344B1 (en) 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
JP3832674B2 (ja) * 1995-10-24 2006-10-11 敏一 中村 抗癌剤
US6855685B2 (en) 1995-10-24 2005-02-15 Toshikazu Nakamura Anti-cancer agent
JP2001505995A (ja) * 1996-11-05 2001-05-08 スミスクライン・ビーチャム・コーポレイション 肝細胞成長因子アンタゴニスト
JP4006058B2 (ja) * 1997-03-11 2007-11-14 第一三共株式会社 多臓器不全予防及び／又は治療剤
ZA982068B (en) * 1997-03-14 1998-09-16 Snow Brand Milk Products Co Ltd Agent for preventing and/or treating cachexia
GB9709453D0 (en) * 1997-05-10 1997-07-02 Imp Cancer Res Tech Polypedtides and their use in therapy
ITMI980179A1 (it) * 1998-01-30 1999-07-30 Dompe Spa Proteine ricombinanti derivate da hgf e msp
ITMI980180A1 (it) * 1998-01-30 1999-07-30 Dompe Spa Proteine ricombinanti derivate da hgf e msp
US20020136721A1 (en) * 1998-02-17 2002-09-26 Schwall Ralph H. Hepatocyte growth factor receptor antagonists and uses thereof
CA2384662A1 (fr) * 1999-09-27 2001-04-05 Human Genome Sciences, Inc. 41 proteines humaines secretees
US20080241835A1 (en) * 1999-11-01 2008-10-02 Genentech, Inc. Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same
EP1233777A4 (fr) * 1999-11-24 2003-07-16 Human Genome Sciences Inc Anticorps, polypeptides et polynucleotides de type mip (proteine intrinseque majeure)
US7129064B2 (en) * 2000-06-22 2006-10-31 Nippon Zenyaku Kogyo Ltd. Canine hepatocyte growth factor
EP1234583A1 (fr) 2001-02-23 2002-08-28 F. Hoffmann-La Roche Ag Conjugués du PEG et du HGF-NK4
GB0110430D0 (en) 2001-04-27 2001-06-20 Medical Res Council Protein variants and uses thereof
US7211240B2 (en) 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
AU2003278807A1 (en) 2002-03-01 2004-08-13 Bracco International B.V. Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
WO2003104429A2 (fr) * 2002-06-10 2003-12-18 Idec Pharmaceuticals Corporation Genes surexprimes par le cancer des ovaires et leur utilisation dans la mise au point de nouvelles therapies
WO2004032847A2 (fr) * 2002-10-07 2004-04-22 Genentech, Inc. Variants du facteur de croissance des hepatocytes
CA2517939C (fr) * 2003-03-03 2015-11-24 Dyax Corp. Peptides presentant une fixation specifique avec le recepteur de hgf (cmet) et ses utilisations
US7407660B2 (en) * 2003-04-16 2008-08-05 Genentech, Inc. Methods and compositions for selective modulation of vascularization
JP4716875B2 (ja) 2003-12-16 2011-07-06 敏一 中村 糖鎖欠損型肝細胞増殖因子
BRPI0417107A (pt) * 2003-12-19 2007-02-06 Genentech Inc fragmento de anticorpo, métodos de preparação do fragmento de anticorpo, ácido nucléico isolado, composições, célula hospedeira e métodos de fabricação e de geração de fragmento de anticorpo
US7807177B2 (en) * 2004-01-27 2010-10-05 Toshikazu Nakamura Segment of glycosylation-deficient HGFalpha-chain
EP1723236A1 (fr) 2004-03-03 2006-11-22 F.Hoffmann-La Roche Ag Procede d'expression recombinante d'un fragment n-terminal du facteur de croissance d'hepatocyte
ATE381576T1 (de) 2004-03-03 2008-01-15 Hoffmann La Roche Verfahren zur aufreinigung eines n-terminalen fragments des hepatozytenwachstumsfaktors
CA2575402A1 (fr) 2004-08-05 2006-02-09 Genentech, Inc. Antagonistes anti-cmet humanises
BRPI0611464A2 (pt) 2005-04-15 2010-09-08 Genentech Inc molécula antagonista de hgf/c-met, métodos de modulação, método para tratar uma condição patológica associada com ativação de c-met, ácido nucléico, célula hospedeira, artigo de fabricação, método para fabricar a molécula antagonista de hgf/c-met e usos de uma molécula antagonista de hgf/c-met
AR070862A1 (es) * 2008-03-06 2010-05-12 Genentech Inc Terapia de combinacion con antagonistas de c- met y her
EP2726098A1 (fr) 2011-06-30 2014-05-07 F.Hoffmann-La Roche Ag Formulations d'anticorps anti-c-met
EP3122900A1 (fr) 2014-03-24 2017-02-01 F. Hoffmann-La Roche AG Traitement du cancer avec des antagonistes de c-met et corrélation de ces derniers avec l'expression de hgf
WO2019027299A2 (fr) * 2017-08-04 2019-02-07 주식회사 에스엘바이젠 Composition pharmaceutique pour la prévention ou le traitement de troubles vasculaires comprenant une cellule souche mésenchymateuse exprimant un facteur de croissance des hépatocytes en tant que principe actif
CN109535243B (zh) * 2019-01-07 2019-09-24 北京诺思兰德生物技术股份有限公司 人肝细胞生长因子突变体及其应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2814981C3 (de) * 1978-04-07 1981-08-06 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Faktor zur Stimulation der Proliferationsrate von Leberzellen
DE2914903C2 (de) * 1979-04-12 1981-08-20 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Leberzellwachstumfaktor
JPS5862116A (ja) * 1981-10-09 1983-04-13 Mitsubishi Chem Ind Ltd 肝細胞の増殖促進物質
JPS6045534A (ja) * 1983-08-22 1985-03-12 Otsuka Pharmaceut Co Ltd 肝実質細胞増殖因子
JPS60243019A (ja) * 1984-05-17 1985-12-03 Mitsubishi Chem Ind Ltd 肝細胞増殖因子
JPH0635480B2 (ja) * 1985-08-23 1994-05-11 大塚製薬株式会社 肝実質細胞増殖因子
JPS62161730A (ja) * 1986-01-10 1987-07-17 Mitsubishi Chem Ind Ltd 細胞増殖因子の産生誘発剤
JP2564486B2 (ja) * 1986-07-14 1996-12-18 修治 橋本 肝細胞増殖因子
US4851341A (en) * 1986-12-19 1989-07-25 Immunex Corporation Immunoaffinity purification system
ES2005159A6 (es) * 1987-04-14 1989-03-01 Inst Llorente S A Procedimiento para diagnostico y seguimiento de hepatopatias mediante determinacion de factor de crecimiento hepatico en plasma yno suero sanguineo.
JPS6427491A (en) * 1987-07-14 1989-01-30 Yasushi Daikuhara Monoclonal antibody
JPH02213A (ja) * 1987-10-19 1990-01-05 Taiho Yakuhin Kogyo Kk 生理活性ペプチド持続製剤
JP3030312B2 (ja) * 1988-12-12 2000-04-10 敏一 中村 成熟肝実質細胞増殖因子（ｉ）
US5179078A (en) * 1989-05-12 1993-01-12 Dana Farber Cancer Institute Method of suppressing tumor formation in vivo
JPH03130091A (ja) * 1989-06-05 1991-06-03 Toyobo Co Ltd 組換ヒト肝実質細胞増殖因子
JP2706704B2 (ja) * 1989-06-05 1998-01-28 敏一 中村 組換ヒト肝実質細胞増殖因子
CA2022752C (fr) * 1989-08-11 1998-07-07 Naomi Kitamura Facteur de croissance des cellules du parenchyme hepatique, gene les encodant, procede de production du facteur, et transformants produisant ledit facteur
JPH03204899A (ja) * 1989-09-21 1991-09-06 Otsuka Pharmaceut Co Ltd ヒト肝再生因子、そのｄｎａ塩基配列、該配列を含むプラスミド及び形質転換体並びにリコンビナント肝再生因子
JPH03255096A (ja) * 1990-03-01 1991-11-13 Toyobo Co Ltd 組換ラット肝実質細胞増殖因子
US5235043A (en) * 1990-04-06 1993-08-10 Synergen, Inc. Production of biologically active, recombinant members of the ngf/bdnf family of neurotrophic proteins
JPH0413696A (ja) * 1990-05-08 1992-01-17 Mochida Pharmaceut Co Ltd 新規生理活性物質
JP2784455B2 (ja) * 1990-05-09 1998-08-06 敏一 中村 肝硬変治療剤
JPH0436189A (ja) * 1990-05-30 1992-02-06 Otsuka Pharmaceut Co Ltd 肝細胞増殖因子の製造方法
DE69133492T2 (de) * 1990-06-11 2006-08-10 Nakamura, Toshikazu Rekombinanter menschlicher Hepatozytwachstumsfaktor und Verfahren zu seiner Herstellung
JP2750372B2 (ja) * 1990-06-19 1998-05-13 敏一 中村 賢疾患治療剤
ATE178354T1 (de) * 1990-07-13 1999-04-15 Snow Brand Milk Products Co Ltd Plasmid das für die aminosäuresequenz von tcf-ii kodierende dns enthalt, transformierte zelle und produktion einer physiologisch aktiven substanz mit ihrer verwendung
JPH04120097A (ja) * 1990-09-07 1992-04-21 Agency Of Ind Science & Technol 肝細胞増殖因子
DE69133349T2 (de) * 1990-09-14 2004-10-07 Us Health Ein nicht-mitogener kompetitiver hgf-antagonist
JP3072628B2 (ja) * 1990-11-19 2000-07-31 敏一 中村 ヒト肝実質細胞増殖因子をコードする染色体ｄｎａ
JP3200609B2 (ja) * 1990-12-28 2001-08-20 敏一 中村 上皮細胞増殖促進剤
US5316921A (en) * 1992-05-18 1994-05-31 Genentech, Inc. Single-chain hepatocyte growth factor variants
US5328837A (en) * 1992-05-18 1994-07-12 Genentech, Inc. Hepatocyte growth factor protease domain variants

Also Published As

Publication number Publication date
DK0642580T3 (da) 2002-12-23
ES2181689T3 (es) 2003-03-01
EP0642580A1 (fr) 1995-03-15
EP0642580B1 (fr) 2002-08-21
US5547856A (en) 1996-08-20
DE69332221T2 (de) 2003-04-17
ATE222603T1 (de) 2002-09-15
DE69332221D1 (de) 2002-09-26
PT642580E (pt) 2003-01-31
WO1993023541A1 (fr) 1993-11-25
JPH07508420A (ja) 1995-09-21
JP2004000236A (ja) 2004-01-08

Similar Documents

Publication Publication Date Title
CA2118012A1 (fr) Variantes du facteur de croissance des hepatocytes
JP6357194B2 (ja) 可動部を備えたハイブリッド免疫グロブリン
JP2020534352A5 (fr)
KR102475799B1 (ko) 비-펩티드 결합을 함유하는 하이브리드 면역글로불린
KR20020026558A (ko) 키메라성 폴리펩타이드, 이의 제조 방법 및 용도
JP2014510518A (ja) Ｈｓａ関連組成物および使用方法
US9045564B2 (en) HSA-related compositions and methods of use
JP6676551B2 (ja) 改変フォンウィルブランド因子
BR122016022033B1 (pt) conjugados de polipeptídeo isolado apresentando atividade pró-coagulante de fator viii, seu uso e composição farmacêutica
TW201534618A (zh) 複合物
JP2005537032A5 (fr)
JP6755318B2 (ja) 突然変異フォン・ヴィレブランド因子
US11046749B2 (en) Chimera protein comprising FVIII and vWF factors, and use thereof
US20220281939A1 (en) Modified tff2 polypeptides
AU622891B2 (en) Cleaved dimers of mullerian inhibiting substance-like polypeptides
EP0293785A2 (fr) Clonage et expression du facteur de croissance transformant simien SS-1
JPH07507270A (ja) フォン・ウィルブランド因子の治療用ドメイン
KR20190063412A (ko) 항체와 생리활성물질의 접합방법
US20050277575A1 (en) Therapeutic compositions and methods for treating diseases that involve angiogenesis
JP5757639B2 (ja) セルピンフィンガー融合ポリペプチド
US11028132B1 (en) Half-life optimized linker composition
KR20240110824A (ko) 릴랙신-2 융합 단백질 유사체 및 이의 사용 방법
KR20190076125A (ko) 경구용 유전자 전달체 및 이의 용도

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued